What is the price target for MXCT stock?
13 analysts have analysed MXCT and the average price target is 4.9 USD. This implies a price increase of 589.94% is expected in the next year compared to the current price of 0.71.
MAXCYTE INC (MXCT) Forecast, Price Target & Analyst Ratings
NASDAQ:MXCT • US57777K1060
Current stock price
0.71 USD
0 (-0.57%)
At close:
0.7047 USD
-0.01 (-0.75%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MAXCYTE INC (MXCT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.08
- Revenue Estimate
- 7.505M
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.90
Upside
+ 589.94%
From current price of $0.71 to mean target of $4.90, Based on 13 analyst forecasts
Low
$2.23
Median
$5.10
High
$7.35
Price Target Revisions
1 Month
-14.88%
3 Months
-24.30%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for MXCT. The average price target is 4.9 USD. This implies a price increase of 589.94% is expected in the next year compared to the current price of 0.71.
The average price target has been revised downward by 24.3% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.08%
MXCT was analyzed by 13 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MXCT.
In the previous month the buy percentage consensus was at a similar level.
MXCT was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-25 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-08-11 | BTIG | Downgrade | Buy -> Neutral |
| 2025-08-07 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-03-12 | Stifel | Maintains | Buy -> Buy |
| 2024-04-23 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-03-13 | BTIG | Maintains | Buy -> Buy |
| 2024-03-13 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-11-29 | Craig-Hallum | Initiate | Buy |
| 2023-10-05 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-03-28 | Stephens & Co. | Reiterate | Overweight |
| 2022-08-15 | BTIG | Maintains | Buy |
| 2021-08-24 | William Blair | Initiate | Outperform |
| 2021-08-24 | BTIG | Initiate | Buy |
| 2021-08-24 | Stephens & Co. | Initiate | Overweight |
| 2021-08-24 | Stifel | Initiate | Buy |
| 2021-08-24 | Cowen & Co. | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.08
- Revenue Estimate
- 7.505M
- Revenue Q2Q
- -27.77%
- EPS Q2Q
- 18.40%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
-17.36%
Revenue (3 Months)
-17.39%
EPS (1 Month)
-28.00%
EPS (3 Months)
-25.00%
Next Earnings Summary
MXCT is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.08 USD and the consensus revenue estimate is 7.50M USD.
The next earnings revenue estimate has been revised downward by 17.39% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 41.288M -6.71% | 38.627M -6.44% | 33.026M -14.50% | 32.541M -1.47% | 38.688M 18.89% | 57.615M 48.92% | 97.732M 69.63% | 146.6M 50.00% | 219.9M 50.00% | 307.86M 40.00% | |
| EBITDA YoY % growth | -44.128M -78.95% | -46.882M -6.24% | -40.194M 14.27% | -27.476M 31.64% | -26.601M 3.18% | -22.44M 15.64% | -9.894M 55.91% | 4.896M 149.48% | N/A | N/A | |
| EBIT YoY % growth | -48.299M -76.53% | -51.197M -6.00% | -44.534M 13.01% | -37.189M 16.49% | -29.153M 21.61% | -6.981M 76.05% | 9.774M 240.01% | 29.32M 199.98% | 54.974M 87.50% | 92.357M 68.00% | |
| Operating Margin | -116.98% | -132.54% | -134.85% | -114.28% | -75.35% | -12.12% | 10.00% | 20.00% | 25.00% | 30.00% | |
| EPS YoY % growth | -0.37 -60.87% | -0.39 -5.41% | -0.37 5.13% | -0.28 25.21% | -0.23 18.26% | -0.20 9.81% | -0.11 45.00% | 0.00 100.00% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 18.40% | -0.08 29.17% | -0.06 28.23% | -0.05 20.66% | -0.06 31.25% | -0.06 34.00% | -0.05 28.94% | -0.04 14.29% |
| Revenue Q2Q % growth | 7.505M -27.77% | 7.273M -14.51% | 7.895M 15.61% | 8.754M 19.92% | 10.2M 35.91% | 10.608M 45.85% | 11.118M 40.82% | 12.954M 47.98% |
| EBITDA Q2Q % growth | -7.227M 29.72% | -7.619M 36.67% | -7.15M 10.48% | -5.944M -78.39% | -8.058M -11.49% | -7.854M -3.09% | -7.548M -5.57% | -6.834M -14.98% |
| EBIT Q2Q % growth | -8.972M 21.16% | -9.44M 33.65% | -9.133M 18.85% | -8.005M -4.34% | -9.486M -5.73% | -8.364M 11.40% | -7.446M 18.47% | -5.916M 26.09% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.15%
EPS Next 5 Year
14.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
17.26%
Revenue Next 5 Year
32.62%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
15.78%
EBIT Next 5 Year
15.97%
MAXCYTE INC / MXCT Forecast FAQ
Can you provide the upcoming earnings date for MAXCYTE INC?
MAXCYTE INC (MXCT) will report earnings on 2026-05-04.
Can you provide the consensus estimates for MAXCYTE INC next earnings?
The consensus EPS estimate for the next earnings of MAXCYTE INC (MXCT) is -0.08 USD and the consensus revenue estimate is 7.50M USD.
What is the expected long term growth rate for MXCT stock?
The expected long term growth rate for MAXCYTE INC (MXCT) is 17.26%.